WhaleCreep

Casdin Capital, LLC 13F holdings, Q4 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-12-31, filed 2021-02-16

Casdin Capital, LLC disclosed 50 US equity positions worth $3.4bn in its Q4 2020 13F filing. Its largest position is NVTA1EUR at 15.3% of the reported book, followed by BLFS and FATE. Versus Q3 2020 it opened 11 new positions, added to 11, reduced 2 and exited 6.

$3.4bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
50
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
15.3%
Largest position
The largest single position as a share of the reported equity book.
62.5%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
17
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2020: 11 new, 11 added, 2 reduced, 6 exited

50 rows
NVTA1EUR INVITAE CORP–15.3%$514m12.30m+36%added
BLFS BIOLIFE SOLUTIONS INCHealthcare8.8%$297m7.44m+27%added
FATE FATE THERAPEUTICS INCHealthcare8.3%$277m3.05m0.0%held
EXK EXACT SCIENCES CORPBasic Materials5.9%$197m1.49m–new
2655787D BLUEPRINT MEDICINES CORP–5.2%$174m1.55m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare4.7%$158m3.81m0.0%held
TWST TWIST BIOSCIENCE CORPHealthcare4.2%$141m1.00m0.0%held
PACB PACIFIC BIOSCIENCES CALIF INHealthcare3.9%$130m5.00m+11%added
DNLI DENALI THERAPEUTICS INCHealthcare3.3%$110m1.31m0.0%held
AGIO AGIOS PHARMACEUTICALS INCHealthcare3.1%$103m2.38m+36%added
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare3.0%$101m780,000+26%added
CDXS CODEXIS INCHealthcare2.8%$94.5m4.33m+8.7%added
SRPT SAREPTA THERAPEUTICS INCHealthcare2.7%$90.4m530,0000.0%held
CDNA CAREDX INCHealthcare2.6%$86.5m1.19m0.0%held
RVMD REVOLUTION MEDICINES INCHealthcare1.9%$64.7m1.63m0.0%held
CNST CONSTELLATION PHARMCETICLS I–1.5%$51.4m1.78m+82%added
GBIOGBX GENERATION BIO CO–1.4%$45.7m1.61m0.0%held
DMTKQ DERMTECH INC–1.3%$44.4m1.37m−4.1%reduced
BNR BURNING ROCK BIOTECH LTDHealthcare1.3%$44.4m1.92m0.0%held
ADPT ADAPTIVE BIOTECHNOLOGIES CORHealthcare1.3%$42.2m713,1250.0%held
CRSP CRISPR THERAPEUTICS AGHealthcare1.2%$40.8m266,4300.0%held
BLUEBIRD BIO INC no ticker–1.2%$39.6m915,0000.0%held
ADVMCHF ADVERUM BIOTECHNOLOGIES INC–1.2%$39.6m3.65m+33%added
ONC BEIGENE LTDHealthcare1.2%$38.8m150,0000.0%held
BEAM BEAM THERAPEUTICS INCHealthcare1.1%$37.6m460,000–new
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–1.0%$35.1m810,000+105%added
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare1.0%$32.4m780,555–new
MAGENTA THERAPEUTICS INC no ticker–0.8%$26.2m3.35m0.0%held
ZLAB ZAI LAB LTDHealthcare0.8%$25.7m190,0000.0%held
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare0.8%$25.5m550,000+90%added
ALEC ALECTOR INCHealthcare0.7%$25.0m1.65m0.0%held
ALLO ALLOGENE THERAPEUTICS INCHealthcare0.7%$23.9m945,0000.0%held
MASS 908 DEVICES INC–0.7%$23.1m406,502–new
TSHA TAYSHA GENE THERAPIES INCHealthcare0.6%$21.8m820,4400.0%held
ORIC ORIC PHARMACEUTICALS INCHealthcare0.6%$20.4m601,515+139%added
BLIUSD PHENOMEX INC–0.5%$17.9m200,0000.0%held
KRON1USD KRONOS BIO INC–0.5%$17.4m583,436–new
SGMOQ SANGAMO THERAPEUTICS INCHealthcare0.5%$16.9m1.08m0.0%held
FULC FULCRUM THERAPEUTICS INCHealthcare0.4%$14.5m1.24m−14%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare0.3%$10.0m450,000–new
BDTX BLACK DIAMOND THERAPEUTICS IHealthcare0.3%$9.3m289,3950.0%held
TURNING POINT THERAPEUTICS I no ticker–0.3%$9.1m75,0000.0%held
SEER SEER INCHealthcare0.3%$8.4m150,000–new
ABCL ABCELLERA BIOLOGICS INCHealthcare0.2%$8.0m200,000–new
DYN DYNE THERAPEUTICS INCHealthcare0.2%$7.8m370,0000.0%held
STOK STOKE THERAPEUTICS INCHealthcare0.2%$7.4m120,0000.0%held
FHTX FOGHORN THERAPEUTICS INCHealthcare0.1%$4.4m216,216–new
BRISTOL-MYERS SQUIBB CO no ticker–0.1%$4.3m6.25m0.0%held
32W CODIAK BIOSCIENCES INC–0.07%$2.5m76,688–new
CCCC C4 THERAPEUTICS INCHealthcare0.04%$1.3m40,000–new

Exited since Q3 2020

6 rows
MYOKEUR MYOKARDIA INC5.3%$119m
AMRSEUR AMYRIS INC1.0%$21.6m
ILMN ILLUMINA INC0.4%$9.3m
ORTXUSD ORCHARD THERAPEUTICS PLC0.3%$7.7m
LEGN LEGEND BIOTECH CORP0.2%$4.3m
DCPHEUR DECIPHERA PHARMACEUTICALS IN0.1%$3.3m

Sector mix

  • Healthcare63.1%
  • Unclassified31.1%
  • Basic Materials5.9%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters